Home›Stock Screener›Colinz Laboratories

Colinz Laboratories Share Price Today | Stock Price & Colinz Laboratories Share Screener

COLINZ Pharmaceuticals & Biotechnology
Live Share Price BSE
₹69.00
▲ 3.50 (5.34%)
2026-11-19 00:00:00

As of November 19, 2026, the live Colinz Laboratories share price (BSE: COLINZ) is ₹69.00, up 5.34% from the previous close, with shares trading between ₹65.66 and ₹69.50 in today's trading session, and a 52-week range of ₹39.80–₹85.92. Track Colinz Laboratories marketcap in USD to gauge the company's total market size. Use the Colinz Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Colinz Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹9 and net income of ₹3, with EBITDA of ₹4, an operating margin of 6.0% and a profit margin of 33.3%.

Colinz Laboratories Market Cap ₹16.97 Cr.
COLINZ P/E Ratio (TTM) 6.50
Colinz Laboratories P/B Ratio 1.43
EPS (TTM) ₹2.04
Dividend Yield -
Debt to Equity 0.05
COLINZ 52 Week High ₹85.92
Colinz Laboratories 52 Week Low ₹39.80
Operating Margin 6.00%
Profit Margin 33.33%
COLINZ Revenue (TTM) ₹9.00
EBITDA ₹4.00
Net Income ₹3.00
Total Assets ₹13.00
Total Equity ₹10.00

Colinz Laboratories Share Price Chart

Track the current stock price of Colinz Laboratories with an interactive chart. Analyse COLINZ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Colinz Laboratories stock quote in one place.

The quote of ₹69.00 sits between the 52-week low of ₹39.80 and the 52-week high of ₹85.92, and the latest session moved 5.34% from the previous close.

Colinz Laboratories Company Profile - Fundamental Screener

Screen Colinz Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for COLINZ shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE923C01011.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE923C01011

Colinz Laboratories Balance Sheet Screener

Screen COLINZ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹13, up from ₹12 in 2025.

Latest statistics put total assets at ₹13 and shareholder funds at ₹10, with a leverage ratio of 0.05.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 13 12 11 10 10 10 9 9 10 10
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 2 2 2 2 2 2 2 2 2 3

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 1 1 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 10 10 9 8 8 7 7 7 7 7
Share Capital 3 3 3 3 4 4 4 4 4 4
Reserves & Surplus 8 7 6 6 4 4 3 3 3 3

Colinz Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Colinz Laboratories income statement and profit fundamentals. Analyze COLINZ quarterly results. Colinz Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹9 and net profit was ₹3, equal to earnings per unit of ₹11.00, at an operating margin of 6%.

In that period expenses were ₹6, interest cost ₹0 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹7 and net profit of ₹1.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 9 7 7 7 7 7 6 8 8 8 8 8 8
Expenses 6 6 6 7 7 6 6 7 7 8 8 8 7

Operating Costs and Margins

EBITDA 4 1 1 1 1 1 1 0 1 1 1 1 1
Operating Profit % 6.00% 7.00% 8.00% 8.00% 9.00% 8.00% 5.00% 4.00% 5.00% 5.00% 5.00% 6.00% 6.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 3 1 1 1 1 1 0 0 0 0 0 0 0
Tax 1 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 3 1 1 1 1 0 0 0 0 0 0 0 0
EPS 11.00 2.04 1.97 1.93 1.82 0.74 0.45 -0.01 0.34 0.65 0.40 0.21 0.21

Colinz Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen COLINZ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹3, and net cash flow was an inflow of ₹3.

Over the same period, investing activities provided ₹0 and financing activities provided ₹0.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 3 -2 1 0 1 2 1 0 0 0
Investing Activities 0 0 0 0 0 0 0 0 0 0

Financing and Net Cash

Financing Activities 0 0 0 0 0 0 0 0 0 0
Net Cash Flow 3 -2 1 1 1 2 1 0 0 0

Colinz Laboratories Shareholding Pattern Screener

See Colinz Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Colinz Laboratories promoter holding and ownership changes for COLINZ on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 50.60%, foreign institutions 0.00%, domestic institutions 0.00% and the public 46.90%, spread across 3,141 shareholders.

The shareholder count was 3,141 in 2026-Sept, compared with 3,174 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 50.60% 50.60% 66.00% 66.00% 66.00% 66.00% 66.00% 66.00%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 46.90% 46.19% 31.22% 31.01% 30.97% 31.04% 30.44% 31.01%
Other Holding 2.50% 3.21% 2.78% 2.99% 3.03% 2.95% 3.56% 2.99%
Shareholder Count 3,141 3,174 3,250 3,212 3,272 3,238 3,216 3,202

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Colinz Laboratories. Colinz Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Colinz Laboratories.

Colinz Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Colinz Laboratories stock. Check COLINZ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Colinz Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Colinz Laboratories Market Events Screener - Corporate Actions

Get Colinz Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Colinz Laboratories stock events that may affect COLINZ share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 29, 2026, with a record date of October 29, 2026.

It is followed by Annual General Meeting dated September 22, 2026 and Quarterly Result Announcement dated July 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-29 2026-10-29 Quarterly Result Announcement NA -1.43%
2026-09-22 2026-09-22 Annual General Meeting NA 0.00%
2026-07-30 2026-07-30 Quarterly Result Announcement NA 0.00%
2026-04-29 2026-04-29 Quarterly Result Announcement NA 0.00%
2026-01-24 2026-01-24 Quarterly Result Announcement NA 0.00%
2025-11-03 2025-11-03 Quarterly Result Announcement NA 0.00%
2025-09-30 2025-09-30 Annual General Meeting NA 0.00%
2025-07-31 2025-07-31 Quarterly Result Announcement NA 0.00%
2025-05-16 2025-05-16 Quarterly Result Announcement NA 0.00%
2025-01-31 2025-01-31 Quarterly Result Announcement NA 0.00%
2024-10-30 2024-10-30 Quarterly Result Announcement NA 0.00%
2024-09-30 2024-09-30 Annual General Meeting NA 0.00%

Colinz Laboratories Competitors Screener - Peer Stocks Comparison

Screen COLINZ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 447,116 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 293,037 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,480 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 119,085 98.10 6,868 22.01% 890 69.60
Zydus Life Science 118,723 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 114,785 41.70 35,059 3.90% 4,158 70.24
Cipla 112,575 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 108,160 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 102,941 26.40 34,145 5.56% 3,503 66.06
Lupin 89,926 17.30 29,039 26.75% 5,356 44.92

Colinz Laboratories Company Announcements - News & Reports Screener

Screen COLINZ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 31, 2026.

The next most recent announcements are dated October 29, 2026 and October 29, 2026.

Date Update Actions
2026-10-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-29 Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015. -
2026-10-29 Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015. -
2026-10-19 Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-01 Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue Rights Issue Preferential Issue QIP) For The Quarter Ended 30.09.2026. -
2026-10-01 Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulation 2015). -
2026-09-29 Closure of Trading Window -
2026-09-23 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-22 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-04 Post Offer Advertisement -
2026-08-27 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-20 Reg. 34 (1) Annual Report. -
2026-08-20 Notice Of Book Closure Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) 2015 & E-Voting Schedule -
2026-08-20 Notice Of 40Th AGM And Book Closure. -
2026-08-12 Updates on Open Offer -
2026-08-06 Updates on Open Offer -
2026-08-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-31 Letter of Offer -
2026-07-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹69.00, within a 52-week range of ₹39.80 to ₹85.92. The P/E ratio is 6.50 and the P/B ratio is 1.43, with earnings per unit of ₹2.04. Market capitalisation stands at ₹16.97 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 21, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.